Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab plus chemoradiotherapy versus chemoradiotherapy alone in first-line locally advanced head and neck squamous cell carcinoma
2016-001456-21Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Avelumab + standard chemoradiotherapy with Placebo + standard chemoradiotherapy (2 arms). Primary endpoint: Progression-free survival. Started Mar 2017; status: completed.
02
Drugs
avelumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2016-001456-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001456-21.